Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer itself in the US. We believe the market reaction has been overdone and the current share price fully discounts any value from the US and China opportunities. Until STX provides further clarity, we have continued to evaluate it based on a US partnering deal. Our modelling suggests an STX-led US launch ....
01 Feb 2021
Shield Therapeutics - Beefing up for the US opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Beefing up for the US opportunity
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
01 Feb 2021 -
Author:
Dr Susie Jana -
Pages:
17
Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer itself in the US. We believe the market reaction has been overdone and the current share price fully discounts any value from the US and China opportunities. Until STX provides further clarity, we have continued to evaluate it based on a US partnering deal. Our modelling suggests an STX-led US launch ....